Call for abstracts is now open for the 5th PPRI Conference 2024: Ensuring access to affordable medicines through innovative policies

➡️Details incl. topics: ppri.goeg.at/ppriconference…
⏳Deadline for abstracts: 20 Dec 2023
📍Conference will take place in Vienna from 25-26 April 2024

What's a fair price for health technologies? Poster with first findings from a review of fair pricing definitions at #ISPOR
ASCERTAIN Gesundheit Österreich

📢Our first newsletter is here! Discover #ASCERTAIN 's mission to improve #healthtech accessibility in Europe. Dive into an interview with Carin Uyl-de Groot and explore project updates, the ASCERTAIN framework, global models, and the ACCESS2MEDS toolbox!🔗access2meds.eu/ascertain-news…

Pleased to see this work published using essential data from the #WorldAlzheimerReport2019 ADI LSE #Discrimination and #Stigma Scale Ultra Short for People Living with #Dementia (DISCUS-Dementia)
pubmed.ncbi.nlm.nih.gov/37650126/ #WorldAlzheimersMonth

Research on effectiveness of interventions for people w. Dementia in Low&Middle Income countries is concentrated in few countries (mainly China) no trials in vast majority of countries. An amazing paper, also because of how it was done onlinelibrary.wiley.com/doi/full/10.10…

Our latest STRiDE Dementia Project paper led by Maximilian Salcher-Konrad reports on enormous work in mapping 340 trials from low & middle income countries on interventions for dementia or mild cognitive impairment. No language restrictions; two-thirds of studies from China
onlinelibrary.wiley.com/doi/full/10.10…

Our most recent STRiDE Dementia Project paper has been published today in Dementia with Cleusa Ferri Fabiana Da Mata ADI elaine mateus Adelina ComasHerrera Doctorado en Ciencia de Enfermería UNAB U. Andrés Bello journals.sagepub.com/doi/10.1177/14… #dementia

Regulated information sources for anticancer drugs in Europe fail to address the information needs of patients, finds study.

If patients lack access to such information, clinical decisions may not align with their preferences and needs, warn researchers
bmj.com/content/380/bm…

Important information about cancer drugs is frequently omitted from official prescription drug information sources for clinicians and patients in Europe. New The BMJ study by researchers from LSE Health Policy Division of Health Policy and Insurance Research University of Sydney King's Global Health & Social Medicine (GHSM) ➡️bit.ly/40uuGMM

Communication of anticancer drug benefits and related uncertainties to patients and clinicians: document analysis of regulated information on prescription drugs in Europe bmj.com/content/380/bm…

Want to learn more about pharmaceutical policy and economics? In a new report commissioned by The Health Foundation #REAL Centre, the Department’s Huseyin Naci & Robin Forrest explain pharmaceutical discovery, development, approval and adoption.

➡️ Access here: bit.ly/41FbIUU

Procurement of medicines can be used as a tool to increase security of supply, affordability, greener manufacturing and other objectives. Curious how? Join the public webinar on optimising public procurement of medicines in the EU👇 #healthUnion #Pharmaceuticals

1/ Drug companies often claim high prices are needed to recoup R&D spending.

But is that true?

In our new JAMA Network Open study, we found that high drug prices don’t necessarily correspond to higher R&D spending.

jamanetwork.com/journals/jaman…

Inmaculada (Inma) Hernández Lucas Berenbrok @UCSDSkaggsSOP